04:24 PM EDT, 03/23/2026 (MT Newswires) -- Sutro Biopharma ( STRO ) reported fiscal 2025 net loss late Monday of $22.49 per diluted share, narrowing from a loss of $29.40 a year earlier.

Analysts polled by FactSet expected $17.81 loss.

Revenue for the year ended Dec. 31 was $102.5 million, up from $62 million a year earlier.

Analysts expected $99.2 million.

As of Dec. 31, cash, cash equivalents and marketable securities stood at $141.4 million, compared with $167.6 million as at Sept. 30.